Literature DB >> 22718491

A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome.

Gerwyn Morris1, Michael Maes.   

Abstract

This paper proposes a neuro-immune model for Myalgic Encephalomyelitis/Chronic fatigue syndrome (ME/CFS). A wide range of immunological and neurological abnormalities have been reported in people suffering from ME/CFS. They include abnormalities in proinflammatory cytokines, raised production of nuclear factor-κB, mitochondrial dysfunctions, autoimmune responses, autonomic disturbances and brain pathology. Raised levels of oxidative and nitrosative stress (O&NS), together with reduced levels of antioxidants are indicative of an immuno-inflammatory pathology. A number of different pathogens have been reported either as triggering or maintaining factors. Our model proposes that initial infection and immune activation caused by a number of possible pathogens leads to a state of chronic peripheral immune activation driven by activated O&NS pathways that lead to progressive damage of self epitopes even when the initial infection has been cleared. Subsequent activation of autoreactive T cells conspiring with O&NS pathways cause further damage and provoke chronic activation of immuno-inflammatory pathways. The subsequent upregulation of proinflammatory compounds may activate microglia via the vagus nerve. Elevated proinflammatory cytokines together with raised O&NS conspire to produce mitochondrial damage. The subsequent ATP deficit together with inflammation and O&NS are responsible for the landmark symptoms of ME/CFS, including post-exertional malaise. Raised levels of O&NS subsequently cause progressive elevation of autoimmune activity facilitated by molecular mimicry, bystander activation or epitope spreading. These processes provoke central nervous system (CNS) activation in an attempt to restore immune homeostatsis. This model proposes that the antagonistic activities of the CNS response to peripheral inflammation, O&NS and chronic immune activation are responsible for the remitting-relapsing nature of ME/CFS. Leads for future research are suggested based on this neuro-immune model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718491     DOI: 10.1007/s11011-012-9324-8

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  190 in total

1.  Superoxide anions induce the maturation of human dendritic cells.

Authors:  Salome Kantengwa; Lan Jornot; Christiane Devenoges; Laurent P Nicod
Journal:  Am J Respir Crit Care Med       Date:  2003-02-01       Impact factor: 21.405

2.  p53 regulates mitochondrial respiration.

Authors:  Satoaki Matoba; Ju-Gyeong Kang; Willmar D Patino; Andrew Wragg; Manfred Boehm; Oksana Gavrilova; Paula J Hurley; Fred Bunz; Paul M Hwang
Journal:  Science       Date:  2006-05-25       Impact factor: 47.728

3.  Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome.

Authors:  D Buchwald; M H Wener; T Pearlman; P Kith
Journal:  J Rheumatol       Date:  1997-02       Impact factor: 4.666

Review 4.  The NF-kappaB regulatory network.

Authors:  Allan R Brasier
Journal:  Cardiovasc Toxicol       Date:  2006       Impact factor: 3.231

5.  Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome.

Authors:  B Manuel y Keenoy; G Moorkens; J Vertommen; I De Leeuw
Journal:  Life Sci       Date:  2001-03-16       Impact factor: 5.037

6.  Differential cytokine regulation by NF-kappaB and AP-1 in Jurkat T-cells.

Authors:  Hazem Khalaf; Jana Jass; Per-Erik Olsson
Journal:  BMC Immunol       Date:  2010-05-27       Impact factor: 3.615

7.  Immunological abnormalities in patients with chronic fatigue syndrome.

Authors:  U Tirelli; G Marotta; S Improta; A Pinto
Journal:  Scand J Immunol       Date:  1994-12       Impact factor: 3.487

8.  Interleukin-1 stimulates the release of dopamine and dihydroxyphenylacetic acid from the hypothalamus in vivo.

Authors:  P S Mohankumar; S Thyagarajan; S K Quadri
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

9.  Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression.

Authors:  Ann Gardner; Richard G Boles
Journal:  Biopsychosoc Med       Date:  2008-02-22

10.  Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis.

Authors:  Lihan Zhang; John Gough; David Christmas; Derek L Mattey; Selwyn C M Richards; Janice Main; Derek Enlander; David Honeybourne; Jon G Ayres; David J Nutt; Jonathan R Kerr
Journal:  J Clin Pathol       Date:  2009-12-02       Impact factor: 3.411

View more
  45 in total

Review 1.  The glutathione system: a new drug target in neuroimmune disorders.

Authors:  Gerwyn Morris; George Anderson; Olivia Dean; Michael Berk; Piotr Galecki; Marta Martin-Subero; Michael Maes
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

2.  Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically Relevant Phenotyping of Women With Chronic Fatigue Syndrome.

Authors:  Matthew C Morris; Katherine E Cooney; Hooman Sedghamiz; Maria Abreu; Fanny Collado; Elizabeth G Balbin; Travis J A Craddock; Nancy G Klimas; Gordon Broderick; Mary Ann Fletcher
Journal:  Clin Ther       Date:  2019-03-28       Impact factor: 3.393

3.  Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome.

Authors:  Øystein Fluge; Olav Mella; Ove Bruland; Kristin Risa; Sissel E Dyrstad; Kine Alme; Ingrid G Rekeland; Dipak Sapkota; Gro V Røsland; Alexander Fosså; Irini Ktoridou-Valen; Sigrid Lunde; Kari Sørland; Katarina Lien; Ingrid Herder; Hanne Thürmer; Merete E Gotaas; Katarzyna A Baranowska; Louis Mlj Bohnen; Christoph Schäfer; Adrian McCann; Kristian Sommerfelt; Lars Helgeland; Per M Ueland; Olav Dahl; Karl J Tronstad
Journal:  JCI Insight       Date:  2016-12-22

4.  Stress management skills, cortisol awakening response, and post-exertional malaise in Chronic Fatigue Syndrome.

Authors:  Daniel L Hall; Emily G Lattie; Michael H Antoni; Mary Ann Fletcher; Sara Czaja; Dolores Perdomo; Nancy G Klimas
Journal:  Psychoneuroendocrinology       Date:  2014-07-06       Impact factor: 4.905

5.  Telephone-administered versus live group cognitive behavioral stress management for adults with CFS.

Authors:  Daniel L Hall; Emily G Lattie; Sara F Milrad; Sara Czaja; Mary Ann Fletcher; Nancy Klimas; Dolores Perdomo; Michael H Antoni
Journal:  J Psychosom Res       Date:  2016-12-08       Impact factor: 3.006

6.  Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome?

Authors:  Jesús Castro-Marrero; Mario D Cordero; María José Segundo; Naia Sáez-Francàs; Natalia Calvo; Lourdes Román-Malo; Luisa Aliste; Tomás Fernández de Sevilla; José Alegre
Journal:  Antioxid Redox Signal       Date:  2014-12-18       Impact factor: 8.401

7.  Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2013-09-10       Impact factor: 3.584

8.  Different Phenotyping Approaches Lead to Dissimilar Biologic Profiles in Men With Chronic Fatigue After Radiation Therapy.

Authors:  Li Rebekah Feng; Kristin Dickinson; Neila Kline; Leorey N Saligan
Journal:  J Pain Symptom Manage       Date:  2016-08-09       Impact factor: 3.612

Review 9.  The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease.

Authors:  Gerwyn Morris; Michael Berk; Andre Carvalho; Javier R Caso; Yolanda Sanz; Ken Walder; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-06-27       Impact factor: 5.590

Review 10.  Nitrosative Stress, Hypernitrosylation, and Autoimmune Responses to Nitrosylated Proteins: New Pathways in Neuroprogressive Disorders Including Depression and Chronic Fatigue Syndrome.

Authors:  Gerwyn Morris; Michael Berk; Hans Klein; Ken Walder; Piotr Galecki; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-06-23       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.